Chromatography Or By Septum Selective As To Material, E.g., Gel Filtration, Molecular Sieve Dialysis, Etc. Patents (Class 530/417)
-
Patent number: 6468733Abstract: The invention concerns a method for elimination of viruses from a biological preparation wherein initially enveloped viruses are eliminated by a solvent-detergent step, then the solvent-detergents are removed by a resin composed of silicon beads and finally the preparation is nanofiltered.Type: GrantFiled: April 27, 2001Date of Patent: October 22, 2002Assignee: Omrix Biopharmaceuticals Inc.Inventors: Israel Nur, Liliana Bar
-
Publication number: 20020143158Abstract: Purification of poly-amino acid-tagged recombinant proteins has been improved by the use of a carboxymethylated aspartate ligand complexed with a third-block transition metal having an oxidation state of 2+and a coordination number of 6. A method for synthesizing the metal ion-CM-Asp complex is also described. Further, the metal ion-CM- Asp complex can be used for screening protein finction.Type: ApplicationFiled: April 19, 2001Publication date: October 3, 2002Inventors: Brian Perry, Paul S. Nelson, Te-Tuan Yang, Thomas H. Smith
-
Publication number: 20020137893Abstract: Methods are provided for large scale purification of neurotrophins, including mature NGF, suitable for clinical use. The methods provide means to separate neurotrophins from various less desirable misprocessed, misfolded, size, glycosylated, or charge forms. Compositions of neurotrophins, including mature NGF, substantially free of these variants are also provided.Type: ApplicationFiled: February 8, 2002Publication date: September 26, 2002Inventors: Louis E. Burton, Charles H. Schmelzer, Joanne T. Beck
-
Patent number: 6455048Abstract: The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. Optionally, the methods further comprise administering antigen presenting cells sensitized with complexes of hsps noncovalently bound to an antigenic molecule. “Antigenic molecule” as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. In a specific embodiment, the effective amounts of the complex are in the range of 0.Type: GrantFiled: November 15, 1999Date of Patent: September 24, 2002Assignee: Fordham UniversityInventors: Pramod K. Srivastava, Rajiv Y. Chandawarkar
-
Patent number: 6455280Abstract: The invention provides the genomic sequence of GSSP-2, GSSP-2 cDNAs and GSSP-2 polypeptides. Further the invention provides polynucleotides including biallelic markers derived from the GSSP-2 gene and from genomic regions flanking the gene. This invention also provides polynucleotides and methods suitable for genotyping a nucleic acid molecule containing sample for one or more biallelic markers of the invention. Further, the invention provides methods to detect a statistical correlation between a biallelic marker allele and a phenotype and/or between a biallelic marker haplotype and a phenotype. The invention also concerns methods and compositions for killing neoplastic cells or inhibiting neoplastic cell growth. In particular, the present invention concerns cell proliferation arresting/inhibiting and apoptosis/necrosis inducing compositions and methods for the treatment of tumors. The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides.Type: GrantFiled: December 28, 2000Date of Patent: September 24, 2002Assignee: Genset S.A.Inventors: Jean-Baptiste Dumas Milne Edwards, Aymeric Duclert, Lydie Bougueleret, Catherine Clusel
-
Patent number: 6451987Abstract: The present invention relates to an ion exchange chromatography process for purifying a peptide from a mixture containing the peptide and related impurities, and to an industrial method including such ion exchange chromatography process.Type: GrantFiled: March 10, 2000Date of Patent: September 17, 2002Assignee: Novo Nordisk A/SInventor: Arne Staby
-
Patent number: 6448374Abstract: A method for the preparation of selected phosphopeptides having anticariogenic and other activities, comprising the steps of completely digesting a soluble monovalent cation salt of casein in solution with a proteolytic enzyme, adding a mineral acid to the solution to adjust the pH to about 4.7, removing any precipitate produced, adding CaCl2 to a level of about 1.0% w/v to cause aggregation of at least the selected phosphopeptides in said digested solution, separating the aggregated phosphopeptides from the solution through a filter having a molecular weight exclusion limit lying substantially within the range 10,000 to 20,000 while passing the bulk of the remaining phosphopeptides and solution, diafiltering the separated phosphopeptides with water through a filter and concentrating and drying the retentate.Type: GrantFiled: March 4, 1994Date of Patent: September 10, 2002Assignee: The University of MelbourneInventor: Eric Charles Reynolds
-
Patent number: 6447780Abstract: The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. Optionally, the methods further comprise administering antigen presenting cells sensitized with complexes of hsps noncovalently bound to an antigenic molecule. “Antigenic molecule” as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. In a specific embodiment; the effective amounts of the complex are in the range of 0.Type: GrantFiled: October 26, 1999Date of Patent: September 10, 2002Assignee: Fordham UniversityInventors: Pramod K. Srivastava, Rajiv Y. Chandawarkar
-
Patent number: 6444211Abstract: Pertactin (formerly 69 kDa protein) is recovered in stable biologically pure form having no detectable adenylate cyclase activity from fermentation broth from the fermentation of Bordetella pertussis as well as from the cells. The broth is processed to selectively remove pertussis toxin (PT) and filamentous haemagglutinin (FHA), the pertactin is precipitated by ammonium sulphate and the precipitate is dissolved in buffer at pH 6.0 to 8.5, the solution then is passed through hydroxyapatite and ion-exchange chromatograph columns before final ultrafiltration. Cells are extracted with urea and the extract ultrafiltered and diafiltered. The pertactin is precipitated from the extract and the precipitate processed as above. In a variation, the broth is contacted with ammonium sulphate to precipitate pertactin, PT and FHA, the precipitate is dissolved and the PT and FHA selectively removed, before the solution is passed to the chromatograph columns.Type: GrantFiled: June 8, 1999Date of Patent: September 3, 2002Assignee: Connaught Laboratories, Inc.Inventors: Gail Jackson, Raafat Fahim, Larry Tan, Pele Chong, John Vose, Michel Klein
-
Patent number: 6444788Abstract: The present invention relates to an ion exchange chromatography process for purifying GLP-1 or an analog or a derivative thereof from a mixture containing said GLP-1 and related impurities, and to an industrial method including such ion exchange chromatography process.Type: GrantFiled: March 13, 2000Date of Patent: September 3, 2002Assignee: Novo Nordisk A/SInventor: Arne Staby
-
Patent number: 6441146Abstract: Pentadentate chelators (PDC) resins are the metal chelate resins capable of forming the octahedral complexes with several polyvalent metal ions including Cu2+, Ni2+, Zn2+ and Co2+ with five coordination sites occupied by the chelator. This results in the best stability of the complexes and in one coordination site free for interaction and selective binding of accessible cysteine/histidine residues and chiefly histidine containing biomolecules such as proteins or peptides etc. Cu-PDC can be used as concentration resins to reduce the volume of a protein solution. It can be used also as a universal support for immobilizing covalently all proteins, using a soluble carbodiimide.Type: GrantFiled: July 13, 1999Date of Patent: August 27, 2002Inventor: Tran Quang Minh
-
Patent number: 6436404Abstract: The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. Optionally, the methods further comprise administering antigen presenting cells sensitized with complexes of hsps noncovalently bound to an antigenic molecule. “Antigenic molecule” as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. In a specific embodiment, the effective amounts of the complex are in the range of 0.Type: GrantFiled: November 15, 1999Date of Patent: August 20, 2002Assignee: Fordham UniversityInventors: Pramod K. Srivastava, Rajiv Y. Chandawarkar
-
Patent number: 6433144Abstract: This invention relates to methods for isolating highly purified mixtures of natural Type I interferon from white blood cells. The invention also relates to highly-purified mixtures of Type I interferon which resemble natural Type I interferon in that the highly purified mixtures of natural Type I interferon includes at least 9 subtypes, i.e., alpha-1, alpha-2, alpha-5, alpha-7, alpha-8, alpha-10, alpha-14, alpha-21 and omega, giving rise to at least 16, and possibly 20 or more molecular species, including alpha-1a, alpha-1new, alpha-2a, alpha-2b, alpha-2c, alpha-5, alpha-5LG, alpha-7, alpha-8a, alpha-8c, alpha-10a, alpha-14a, alphal4-b, alpha 14-c, alpha-14LG, alpha-21a, alpha-21b, alpha-21c, omega and omega LG.Type: GrantFiled: January 12, 1999Date of Patent: August 13, 2002Assignee: Viragen, Inc.Inventors: Joseph P. Morris, Duy Nguyen, James Kappelman, Michael D. Potter, Mead M. McCabe, Reza Ziai, Stephen Feldman, Hipolito Hartman
-
Patent number: 6428704Abstract: A method for determining hemoglobins is provided which is suitable for determination of stable hemoglobin A1c. A method for determining hemoglobins by cation exchange liquid chromatography wherein an eluent is used containing a chaotropic ion and further an inorganic acid, an organic acid and/or any salt thereof having a buffer capacity in the 4.0-6.8 pH range.Type: GrantFiled: February 7, 2001Date of Patent: August 6, 2002Assignee: Sekisui Chemical Co., Ltd.Inventors: Yuji Setoguchi, Kazuyuki Oishi, Kazuhiko Shimada, Toshiki Kawabe, Takayuki Oka
-
Patent number: 6423233Abstract: Object of the invention is a process for the chromatographic purification of cyclosporin A from a crude product containing cyclosporin complex by using a column filled with silica gel and by the application of multistep chromatography with a column filled with normal phase silica gel and by a solvent mixture containing toluene as the major component.Type: GrantFiled: August 15, 2000Date of Patent: July 23, 2002Assignee: Biogal Gyogyszergyar Rt.Inventors: Vilmos Kéri, Árvai Edit Nagyné, Lajos Deák, Györgyné Makó, Istvánné Miskolczy
-
Patent number: 6423831Abstract: Methods are provided for large scale purification of neurotrophins, including mature NGF, suitable for clinical use. The methods provide means to separate neurotrophins from various less desirable misprocessed, misfolded, size, glycosylated, or charge forms. Compositions of neurotrophins, including mature NGF, substantially free of these variants are also provided.Type: GrantFiled: September 29, 2000Date of Patent: July 23, 2002Assignee: Genentech, Inc.Inventors: Louis E. Burton, Charles H. Schmelzer, Joanne T. Beck
-
Patent number: 6410713Abstract: Human heat-shock protein-binding proteins (HspBP-1 and HspBP-2) are disclosed with the polynucleotides which identify and encode them. Genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding heat-shock protein-binding proteins (HspBP) are also disclosed and a method for producing HspBP polypeptides. Also provided is a process of using HspBP for abrogating heat shock-protein activity in the prevention or treatment of diseases associated with such activity.Type: GrantFiled: November 19, 1999Date of Patent: June 25, 2002Inventors: Vincent Guerriero, Deborah A. Raynes
-
Patent number: 6399070Abstract: The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. Optionally, the methods further comprise administering antigen presenting cells sensitized with complexes of hsps noncovalently bound to an antigenic molecule. “Antigenic molecule” as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. In a specific embodiment, the effective amounts of the complex are in the range of 0.Type: GrantFiled: November 15, 1999Date of Patent: June 4, 2002Assignee: Fordham UniversityInventors: Pramod K. Srivastava, Rajiv Y. Chandawarkar
-
Patent number: 6399069Abstract: The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. Optionally, the methods further comprise administering antigen presenting cells sensitized with complexes of hsps noncovalently bound to an antigenic molecule. “Antigenic molecule” as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. In a specific embodiment, the effective amounts of the complex are in the range of 0.Type: GrantFiled: November 15, 1999Date of Patent: June 4, 2002Assignee: Fordham UniversityInventors: Pramod K. Srivastava, Rajiv Y. Chandawarkar
-
Patent number: 6395884Abstract: A therepeutic method whereby an individual suspected of having an &agr;-galactosidase A deficiency, such as Fabry disease, is treated either with (1) human cells that have been genetically modified to overexpress and secrete human &agr;-gal A, or (2) purified human &agr;-gal A obtained from cultured, genetically modified human cells.Type: GrantFiled: April 6, 2000Date of Patent: May 28, 2002Assignee: Transkaryotic Therapies, Inc.Inventors: Richard F. Selden, Marianne Borowski, Frances P. Gillispie, Carol M. Kinoshita, Douglas A. Treco, Melanie D. Williams
-
Patent number: 6391306Abstract: The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. Optionally, the methods further comprise administering antigen presenting cells sensitized with complexes of hsps noncovalently bound to an antigenic molecule. “Antigenic molecule” as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. In a specific embodiment, the effective amounts of the complex are in the range of 0.Type: GrantFiled: November 15, 1999Date of Patent: May 21, 2002Assignee: Fordham UniversityInventors: Pramod K. Srivastava, Rajiv Y. Chandawarkar
-
Patent number: 6387374Abstract: The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. Optionally, the methods further comprise administering antigen presenting cells sensitized with complexes of hsps noncovalently bound to an antigenic molecule. “Antigenic molecule” as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. In a specific embodiment, the effective amounts of the complex are in the range of 0.Type: GrantFiled: November 15, 1999Date of Patent: May 14, 2002Assignee: Fordham UniversityInventors: Pramod K. Srivastava, Rajiv Y. Chandawarkar
-
Patent number: 6387877Abstract: The invention relates to a method of removing endotoxin from preparations of alpha-1-acid glycoprotein (orosomucoid) by contact with a finely divided non-toxic resin such as fumed silica. The invention also relates to a purification process for alpha-1-acid glycoprotein which includes this deprogenation step, and to the depyrogenated product and its clinical uses.Type: GrantFiled: January 25, 1999Date of Patent: May 14, 2002Assignee: National Blood AuthorityInventors: John Edward More, Jacqueline Rott, David Roger Lewin
-
Publication number: 20020055145Abstract: The invention is directed to methods for purifying Troponin I, particularly recombinant Tropnin I produced in a bacterial expression system. Recombinant Tropnin I can be advantageously purified after reversibly protecting the free sulfhydryl groups, e.g., by forming sulfates. In a specific example, Tropnin I reacted with sodium tetrafhionate yielded sulfitolyzed Tropnin I, which was purified by chromatography on an anion exchanger, followed by hydrophobic interaction chromatography. Facile deprotection of the sulfhydryl groups yields a highly purified product ready for refolding.Type: ApplicationFiled: November 30, 2001Publication date: May 9, 2002Applicant: Diosynth RTP, Inc.Inventors: Gregory Conn, Brian Reardon, Xianfang Zeng, Chenming Zhang
-
Patent number: 6383491Abstract: The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. Optionally, the methods further comprise administering antigen presenting cells sensitized with complexes of hsps noncovalently bound to an antigenic molecule. “Antigenic molecule” as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. In a specific embodiment; the effective amounts of the complex are in the range of 0.Type: GrantFiled: November 15, 1999Date of Patent: May 7, 2002Assignee: Fordham UniversityInventors: Pramod K. Srivastava, Rajiv Y. Chandawarkar
-
Patent number: 6383492Abstract: The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. Optionally, the methods further comprise administering antigen presenting cells sensitized with complexes of hsps noncovalently bound to an antigenic molecule. “Antigenic molecule” as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. In a specific embodiment, the effective amounts of the complex are in the range of 0.Type: GrantFiled: November 15, 1999Date of Patent: May 7, 2002Assignee: Fordham UniversityInventors: Pramod K. Srivastava, Rajiv Y. Chandawarkar
-
Patent number: 6383493Abstract: The present invention relates to methods and compositions for eliciting an immune response and the prevention-and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. Optionally, the methods further comprise administering antigen presenting cells sensitized with complexes-of hsps noncovalently bound to an antigenic molecule. “Antigenic molecule” as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. In a specific embodiment, the effective amounts of the complex are in the range of 0.Type: GrantFiled: November 15, 1999Date of Patent: May 7, 2002Assignee: Fordham UniversityInventors: Pramod K. Srivastava, Rajiv Y. Chandawarkar
-
Patent number: 6383494Abstract: The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. Optionally, the methods further comprise administering antigen presenting cells sensitized with complexes of hsps noncovalently bound to an antigenic molecule. “Antigenic molecule” as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. In a specific embodiment, the effective amounts of the complex are in the range of 0.Type: GrantFiled: November 15, 1999Date of Patent: May 7, 2002Assignee: Fordham UniversityInventors: Pramod K. Srivastava, Rajiv Y. Chandawarkar
-
Publication number: 20020051972Abstract: NTNR&agr;, NTNR&agr; extracellular domain (ECD), NTNR&agr; variants, chimeric NTNR&agr; (e.g., NTNR&agr; immunoadhesion), and antibodies which bind thereto (including agonist and neutralizing antibodies) are disclosed. Various uses for these molecules are described, including methods to modulate cell activity and survival by response to NTNR&agr;-ligands, for example NTN, by providing NTNR&agr; to the cell.Type: ApplicationFiled: September 1, 1999Publication date: May 2, 2002Inventors: ROBERT D. KLEIN, ARNON ROSENTHAL
-
Patent number: 6379672Abstract: The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. Optionally, the methods further comprise administering antigen presenting cells sensitized with complexes of hsps noncovalently bound to an antigenic molecule. “Antigenic molecule” as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. In a specific embodiment, the effective amounts of the complex are in the range of 0.Type: GrantFiled: November 15, 1999Date of Patent: April 30, 2002Assignee: Fordham UniversityInventors: Pramod K. Srivastava, Rajiv Y. Chandawarkar
-
Patent number: 6380366Abstract: The present invention relates to cartilage extracts and to a method of producing the same. Shark cartilage extracts having anti-angiogenic, anti-tumor, anti-inflammatory and anti-collagenolytic activities have been obtained by an improved process. The process comprises the steps of obtaining a crude cartilage extract in an aqueous solution, this crude extract being fractionated to recover molecules of a molecular weight less than about 500 kDa. Some of the biologically active components of the extract are prepared by further fractionation. The cartilage extract can be used for treating diseases or conditions having etiological components selected from the group consisting of tumor proliferation, angiogenesis, inflammation, metalloprotease activity and collagenolysis. Several cosmetic applications based on the capacity of the liquid extract to improve skin conditions are also disclosed. A simple and efficient process for the preparation of cartilage extracts is also disclosed.Type: GrantFiled: February 15, 2000Date of Patent: April 30, 2002Assignee: Les Laboratoires Aeterna Inc.Inventors: Éric Dupont, Paul Brazeau, Christina Juneau, Richard Béliveau
-
Patent number: 6380365Abstract: The invention concerns the use of a coiled coil protein which is capable of forming a homodimer which dissociates into monomers on change of temperature, in a method of isolating a ligand or desired protein from a sample. A method of isolating a ligand which binds to the coiled coil protein is described as well as methods of isolating a desired protein which is tagged with a coiled coil protein or a ligand which binds to a coiled coil protein, or is tagged with a coiled coil protein monomer.Type: GrantFiled: May 5, 1999Date of Patent: April 30, 2002Assignee: Affitech ASInventors: Bo Akerström, Tommy Cedervall
-
Patent number: 6376218Abstract: The present invention provides an expression system for producing recombinant human erythropoietin (rhEPO) exhibiting biological activity and immunochemical properties of the native human erythropoietin (hEPO). Also provided is an improved method for purifying rhEPO from culture medium by two-step column chromatography.Type: GrantFiled: December 7, 1998Date of Patent: April 23, 2002Assignee: Research Development FoundationInventors: Li-Wei Hsu, Su-Chen Chang
-
Patent number: 6375953Abstract: The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. optionally, the methods further comprise administering antigen presenting cells sensitized with complexes of hsps noncovalently bound to an antigenic molecule. “Antigenic molecule” as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. In a specific embodiment, the effective amounts of the complex are in the range of 0.Type: GrantFiled: November 15, 1999Date of Patent: April 23, 2002Assignee: Fordham UniversityInventors: Pramod K. Srivastava, Rajiv Y. Chandawarkar
-
Publication number: 20020045211Abstract: Expression systems are disclosed for the direct expression of peptide products into the culture media where genetically engineered host cells are grown. High yield was achieved with novel vectors, a special selection of hosts, and/or fermentation processes which include careful control of cell growth rate, and use of an inducer during growth phase. Special vectors are provided which include control regions having multiple promoters linked operably with coding regions encoding a signal peptide upstream from a coding region encoding the peptide of interest. Multiple transcription cassettes are also used to increase yield. The production of amidated peptides using the expression systems is also disclosed.Type: ApplicationFiled: February 9, 2001Publication date: April 18, 2002Applicant: Unigene Laboratories, Inc.Inventors: Nozer M. Mehta, Angelo P. Consalvo, Martha V.L. Ray, Christopher P. Meenan
-
Publication number: 20020040873Abstract: The instant invention relates to a method and an apparatus useful for purifying DNA sequencing reaction products. Briefly, a gel filtration medium is combined with a molecular cutoff filter in a single apparatus to isolate DNA sequencing fragments from the sequencing template, enzyme, salt and nucleotides. A preferred embodiment of the instant apparatus depicted in FIG. 1 shows a cylindrical housing having openings at the top and bottom of the housing. The housing may take forms other than cylindrical, e.g., rectangular, octagonal, etc.Type: ApplicationFiled: June 7, 2001Publication date: April 11, 2002Inventors: Johan Wahlberg, R. Scott Duthie, Peter Hewitt
-
Patent number: 6362320Abstract: A process for purifying hepatitis B viral surface antigen comprising the preS2 peptide from the cells of a recombinant organism is carried out by a sequence of steps which includes the step of disrupting the cells using a buffer containing a chaotropic salt to obtain a cell homogenate and the step of alkalifying the cell homogenate to a pH ranging from 11.0 to 13.5.Type: GrantFiled: November 2, 1999Date of Patent: March 26, 2002Assignee: LG Chemical LimitedInventors: Soon-Jae Park, Young-Mee Lee, Kyung-Hee Yoon, Kook-Jin Lim, Young-Sun Kwon
-
Publication number: 20020035241Abstract: A process separates and/or isolates plasma proteins, especially human plasma proteins, from a mixture containing plasma proteins, wherein the mixture is applied to a separation medium having an annular design and having a layer of application medium applied thereon; the separation medium having the annular design is rotated essentially vertically about an axis which is defined in the direction of flow of the mixture through the separation medium having the annular design; an eluent is passed through the separation medium having the annular design; and fractions exiting at the end of the separation medium having the annular design are collected.Type: ApplicationFiled: June 13, 2001Publication date: March 21, 2002Inventors: Andrea Buchacher, Djuro Josic, Gerhard Gruber
-
Patent number: 6350590Abstract: The present invention relates to a process for the controlled enzymatic cleavage of purified and depigmented active allergenic proteins from indoor and outdoor source materials, which process produces fragments of allergens that retain the the natural T-lymphocyte stimulating epitopes, but are depleted of IgE-binding B-cell epitopes and complement-activating agents. The invention also relates to the new pharmaceutical products. These allergen fragments do not exhibit the disadvantages of conventional allergenic extracts for immunotherapy and can be safely used to induce a state of specific T-cell anergy and immunological tolerance in allergic human beings.Type: GrantFiled: June 23, 2000Date of Patent: February 26, 2002Assignee: C.B.F. Leti, S.A.Inventors: Lubertus Berrens, Maria Leticia Gonzales Romano, Maria Teresa Gallego Camara
-
Patent number: 6346245Abstract: A procedure is described for obtaining valuable endoproteases (or zonases) from hatchery-produced Atlantic salmon eggs. Synchronized hatching by for instance elevated temperature, is followed by filtration through cheese cloth. The filtrate (hatching fluid) may be stored for months or year (depending on conditions) without loss of activity. Extraneous matters are removed by centrifugation (16,000 g, 2×15 min) after addition of urea (2 or 4 M, or more). High purity zonases are obtained by simple chromatographic procedures (gel filtration, affinity chromatography, isoelectric focusing), yielding sequence-grade purity after all three steps are performed in sequence. All preparations of salmon zonases exhibit valuable enzymatic properties with regard to proteolysis, both in terms of catalysis and stability.Type: GrantFiled: June 8, 2000Date of Patent: February 12, 2002Assignee: Aqua Bio Technology ASInventors: Bernt Th. Walther, Chunjun J. Rong
-
Patent number: 6342367Abstract: Disclosed is an economical method for the preparation of chondroitin sulfates A and C useful as an effective ingredient of medicaments from fish scales as a waste material discharged from fishery in large quantities. Fish scales are enzymatically decomposed in an aqueous medium in the presence of a protease to isolate the chondroitin sulfate compounds and by-product polypeptides followed by removal of the by-product polypeptides from the aqueous solution by a cation-exchange treatment and then the aqueous solution of the chondroitin sulfate compounds is subjected to fractional precipitation by the addition of ethyl alcohol as the precipitant.Type: GrantFiled: February 25, 2000Date of Patent: January 29, 2002Assignee: Japan as represented by Secretary of Agency of Industrial Science and TechnologyInventors: Toshihisa Sumi, Hideki Ohba, Toru Ikegami, Masao Shibata, Tsuyoshi Sakaki, Imre Sallay, Sung Soo Park
-
Patent number: 6338849Abstract: A process of preparing a double-sterilized immunoglobulin product for intravenous injection includes dissolving Cohn's component II in distilled ice water, and adjusting to the desired pH using acetic acid. A filter is used to remove alcohol and salt and establish a desired sodium ion concentration, and the immunoglobulin concentration is adjusted to form interim product, which is bottled. The bottle is filled with gaseous carbon dioxide to achieve a pressure of 0.7 to 200 kPa, sealed in the absence of any protectant, and sterilized. The interim product is filtered, concentrated to achieve an immunoglobulin concentration of 5% to 10%, adjusted to a desired pH, filtered to remove bacteria, and stored at room temperature for 21 days. Glucose is added in order to change the osmotic pressure equilibrium of said interim product to form final product.Type: GrantFiled: February 25, 2000Date of Patent: January 15, 2002Assignee: Chengdu Shuyang Pharmaceutical FactoryInventors: Aimin Chen, Shaowen Fan, Chao Zhou
-
Publication number: 20010047086Abstract: An effective technique for the high throughput screening of displacers is described. In this technique, potential displacers are employed to displace a biomolecule (e.g., protein) adsorbed on a chromatographic resin in small-scale batch displacement experiments. The amount of protein displaced from a specific resin by a defined concentration of displacer is determined by monitoring the supermatant for the protein. By evaluating the displaced protein rather than the displacer itself, this technique enables a single detection technique (e.g., absorbance, fluorescence, etc.) to be employed for all batch displacement experiments. By monitoring the amount of protein displaced, the effacy of a large number of potential displacers can be rapidly evaluated. The entire experimental procedure can be carried out rapidly and is thus amenable to high throughput parallel screening of molecules possessing a large range of affinities and physico-chemical properties.Type: ApplicationFiled: February 23, 2001Publication date: November 29, 2001Inventors: Steven M. Cramer, Kaushal Rege, Jonathan S. Dordick
-
Patent number: 6322997Abstract: The invention herein provides a method for recovering a polypeptide comprising exposing a composition comprising a polypeptide to a reagent which binds to, or modifies, the polypeptide, wherein the reagent is immobilized on a solid phase; and then passing the composition through a filter bearing a charge which is opposite to the charge of the reagent in the composition, so as to remove leached reagent from the composition.Type: GrantFiled: December 14, 1999Date of Patent: November 27, 2001Assignee: Genentech, Inc.Inventors: Gregory S. Blank, Daljit S. Narindray, Gerardo A. Zapata
-
Patent number: 6319685Abstract: Purified enzymatic compositions are provided having alpha-amidating enzymes capable of catalyzing the conversion of a peptidyl compound having a C-terminal glycine residue to a corresponding peptidyl amide having an amino group in place of the C-terminal glycine. The purified compositions have specific activities above 25 mU per mg protein and are sufficiently free of proteases to allow effective catalysis of even peptidyl compounds having L-amino acids. Biologically important alpha-amidated products such as calcitonin and other regulatory hormones are efficiently produced using the alpha-amidation reaction catalyzed by the enzymes. Purification by size exclusion chromatography in combination with strong anion exchange chromatography results in homogeneous enzyme species which are used to prepare antibodies specific for the alpha-amidating enzyme. A gene capable of expressing the alpha-amidating enzyme is ligated into an expression vector and transformed into a host cell capable of expressing the gene.Type: GrantFiled: August 14, 1987Date of Patent: November 20, 2001Assignee: Unigene Laboratories, Inc.Inventors: James P. Gilligan, Barry N. Jones
-
Patent number: 6319868Abstract: Porous zirconia or zirconium-containing particles, methods of making such particles and methods of using such particles including modifications to the surface of the particles are described. The method comprises heating zirconia particles to provide a substantially homogeneously liquid melt, quenching the particles of melt to effect spinodal decomposition to provide quench particles of a silica rich phase and a zirconia rich phase, annealing the quenched particles to provide non porous solid particles of zirconia and silica and, leaching the silica from these particles to produce porous solid zirconia particles comprising a three dimensionally substantially continuous interpenetrating network of interconnected pores.Type: GrantFiled: March 1, 1999Date of Patent: November 20, 2001Assignee: Monash UniversityInventors: Mary Susan Jean Gani, Hans-Jurgen Wirth, Marie Isabel Aguilar, Milton Thomas William Hearn, Donald George Vanselow, Philip Hong Ning Cheang, Kjell-Ove Eriksson
-
Patent number: 6316604Abstract: The present invention relates to the C3b/C4b receptor (CR1) gene and its encoded protein. The invention also relates to CR1 nucleic acid sequences and fragments thereof comprising 70 nucleotides and their encoded peptides or proteins comprising 24 amino acids. The invention further provides for the expression of the CR1 protein and fragments thereof. The genes and proteins of the invention have uses in diagnosis and therapy of disorders involving complement activity, and various immune system or inflammatory disorders. In specific embodiments of the present invention detailed in the examples sections infra, the cloning, nucleotide sequence, and deduced amino acid sequence of a full-length CR1 cDNA and fragments thereof are described. The expression of the CR1 protein and fragments thereof is also described. Also described is the expression of a secreted CR1 molecule lacking a transmembrane region.Type: GrantFiled: June 5, 1995Date of Patent: November 13, 2001Assignee: Avant Immunotherapeutics, Inc.Inventors: Douglas T. Fearon, Lloyd B. Klickstein, Winnie W. Wong, Gerald R. Carson, Michael F. Concino, Stephen H. Ip, Savvas C. Makrides, Henry C. Marsh, Jr.
-
Patent number: 6310186Abstract: This invention relates to the purification of biological preparations such as proteins and nucleic acids, especially for example proteins that have been produced by recombinant DNA techniques in bacteria. In a particular embodiment, the invention concerns improved methods for reducing the content of contaminants in biological preparations, e.g. recombinant proteins produced in host bacteria.Type: GrantFiled: April 3, 2000Date of Patent: October 30, 2001Inventors: Mark Jonathon Wilson, Michael Denis Johnston, Deirdre Anne Glenn, Sean Patrick Gallagher
-
Patent number: 6307031Abstract: A peptide containing a sequence for the first fifteen amino acids from the N-terminal of Asn-Leu-Val-Glu-Phe-Gly-Lys-Met-Ile-Glu-Cys-Ala-Ile-Arg-Asn is used in a cell culture medium to promote cell growth in vitro and in the treatment of wounds. A method of preparation of the peptide is also claimed.Type: GrantFiled: June 3, 1996Date of Patent: October 23, 2001Inventor: Binie V. Lipps
-
Patent number: 6306306Abstract: The present invention relates to a novel chromatographic process which is suitable for the purification of cyclosporin-containing crude extracts on industrial scale. In this process, the conventional preparative chromatographic separation methods are completely or at least partially replaced by the simulated moving bed method (SMB). The cyclosporin A obtained corresponds both to the quality requirements of USP XXIII and of EUROPEAN PHARMACOPOEIA, 2nd Edition 1995.Type: GrantFiled: March 21, 1997Date of Patent: October 23, 2001Assignee: Arzneimittelwerk DresdenInventors: Ulrich Voigt, Joachim Kinkel, Roland Hempel, Roger-Marc Nicoud